Comparative Pharmacology
Head-to-head clinical analysis: LIMBITROL versus LORAZEPAM INTENSOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIMBITROL versus LORAZEPAM INTENSOL.
LIMBITROL vs LORAZEPAM INTENSOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Limbitrol is a combination of chlordiazepoxide (a benzodiazepine) and amitriptyline (a tricyclic antidepressant). Chlordiazepoxide enhances GABA-A receptor activity, producing anxiolytic and sedative effects. Amitriptyline inhibits serotonin and norepinephrine reuptake, elevating mood and reducing pain. The combination is used for depression with anxiety.
Benzodiazepine that enhances GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.
1-2 tablets (5 mg chlordiazepoxide / 12.5 mg amitriptyline per tablet) orally 3-4 times daily. Maximum 6 tablets per day in divided doses.
0.5-2 mg orally every 6-8 hours as needed. Maximum 4 mg/day.
None Documented
None Documented
Amitriptyline: 20-30 hours (range 10-46 h) with a terminal elimination half-life of ~24 h; clinical significance requires 7-14 days to reach steady state. Chlordiazepoxide: 5-30 hours (up to 48 h for active metabolite desmethylchlordiazepoxide).
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged in elderly (15-20 hours) and patients with hepatic impairment (up to 30-40 hours).
Renal (approximately 70-80% as metabolites, 1-3% unchanged) and fecal (20-30% via biliary elimination for chlordiazepoxide component; amitriptyline is primarily excreted renally as metabolites, 10-15% unchanged).
Renal excretion of glucuronide conjugates; <1% unchanged drug excreted renally. Fecal elimination accounts for approximately 10% of administered dose.
Category C
Category D/X
Benzodiazepine/Tricyclic Antidepressant Combination
Benzodiazepine